Table 2.
Metachronous GA and details
| No | Age | Sex | PGL pathology | Lugano stage | Tx for PGL | Interval (months) from PGL to GA | GA pathology | Stage for GA | Tx for GA | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
72 |
F |
DLBCL |
II1 |
CHOP×3 |
42.6 |
sig |
m |
distal gastrectomy |
Alive for 3.7 m after GA |
| + | ||||||||||
| 40 Gy/20fr | ||||||||||
| 2 |
62 |
M |
DLBCL |
I |
CHOP×3 |
64.3 |
W/D AC |
m |
ESD |
Alive for 47.7 m after GA |
| + | ||||||||||
| 40.5 Gy/27fr | ||||||||||
| 3 |
70 |
M |
DLBCL |
II1 |
CHOP×3 |
45.9 |
W to M/D AC |
m |
ESD |
Alive for 71.6 m after GA |
| + | ||||||||||
| 40.5 Gy/27fr | ||||||||||
| 4 |
68 |
F |
DLBCL |
I |
CHOP×3 |
90.8 |
W/D AC |
m |
ESD |
Alive for 31.8 m after GA |
| + | ||||||||||
| 40.5 Gy/27fr | ||||||||||
| 5 |
70 |
M |
DLBCL |
II1 |
CHOP×3 |
16.0 |
W/D AC |
sm |
EMR→partial gastrectomy |
Dead for 36.9 m after GA |
| + | ||||||||||
| 40.5 Gy/27fr | ||||||||||
| 6 |
63 |
M |
DLBCL |
IV |
R×8-CHOP×8 |
30.2 |
W to P/D AC |
se |
total gastrectomy |
Dead for 12.0 m after GA |
| + | ||||||||||
| 40.5 Gy/27fr | ||||||||||
| 7 |
36 |
M |
MALT |
II1 |
R×8-CHOP×3 |
42.1 |
sig |
m |
partial gastrectomy |
Alive for 20.6 m after GA |
| + |
+ |
|||||||||
| DLBCL |
40 G y/20fr |
|||||||||
| 8 |
63 |
M |
DLBCL |
II1 |
R×8-CHOP×6 |
73.7 |
sig |
m |
EMR |
Alive for 16.6 m after GA |
| + | ||||||||||
| 40.5 Gy/27fr | ||||||||||
| 9 |
66 |
F |
MALT |
II1 |
CHOP×3 |
17.5 |
sig |
m |
EMR |
Alive for 69.3 m after GA |
| + |
+ |
|||||||||
| DLBCL |
40.5 Gy/27fr |
|||||||||
| 10 |
73 |
F |
MALT |
I |
CHOP×4 |
7.9 |
W/D AC |
m |
EMR |
Alive for 70.2 m after GA |
| + |
+ |
|||||||||
| DLBCL | 40.5 Gy/27fr |
sig: signet-ring cell carcinoma.
W/D: well differentiated.
M/D: moderately differentiated.
P/D: poorly differentiated.
AC: adenocarcinoma.
PGL: primary gastric lymphoma.
R: rituximab.
Tx: treatment.
GA: gastric adenocarcinoma.
CHOP: cyclophosphamide, hydroxydaunorubicin, vincristine and prednisolone.